Table 1.
Protein Family | System 1 | Exposure Regime | Effect 3 | Study | |
---|---|---|---|---|---|
Cr(VI) Dose/Concentration 2 | Duration | ||||
Small HSP | Rat lung epithelial cells | 10 µM | 24 h | Increased HSP10 protein levels | [42] |
HaCaT cells | 7.4 µM | 24 h | Increased HSP27 (HSPB1) mRNA and protein levels; Reduced HSP27 (HSPB1) phosphorylation | [43] | |
Human primary skin fibroblasts | 1 µM | 16 h | Increased protein levels of phosphorylated HSP27 | [44] | |
BNL CL.2 cells | 15 µM | 3 h | Increased liver HSP27 protein levels | [45] | |
ICR mice | 10 mg/kg body weight (intraperitoneal injection) | 8 weeks | |||
BEAS-2B cells | 10 µM | 4 h | Unchanged HSP27 (HSPB1) mRNA levels | [46] | |
Hsp40 | BEAS-2B cells | 10 µM | 4 h | Decreased HSP40 mRNA levels | [46] |
HSP60 | BEAS-2B cells | 4 h | Decreased HSP60 (HSPD1) mRNA levels | ||
Rat lung epithelial cells | 24 h | Increased HSP60 protein levels | [42] | ||
HSP70 | BEAS-2B cells | 1 µM | 48 h | Unchanged Hsp72 (HSPA1A) protein levels; Decreased Hsp72 (HSPA1A) mRNA levels | [47] |
10 µM | 4 h | Unchanged HSP70 (HSPA6), HSP70.1 (HSPA1) and HSP71 (HSPA8) mRNA levels | [46] | ||
Sprague-Dawley rats | 0.25 mg/kg body weight (intratracheal instillation) | 3 days | HSP70 mRNA levels increased in the lungs and unchanged in the liver; Unchanged HSP60, Grp75 and Grp94 mRNA levels in both lungs and liver | [48] | |
HT29 | 10 or 50 µM | 6 h | Increased Hsp72 (HSPA1A) mRNA levels | [49] | |
HepG2 cells | 0.5 or 1 µM | ||||
0.625–10 µM | 48 h | Induction of HSP70 and Grp78 (HSPA5) promoters for [Cr(VI)] ≥ 5 µM | [50] | ||
100 µM | 3 h | Unchanged HSP70 mRNA levels | [51] | ||
Primary culture of rat granulosa cells | 10 µM | 12 or 24 h | Decreased HSP70 protein levels | [52] | |
L-02 cells | 16 or 32 µM | 24 h | Decreased HSP70 proteins levels | [53] | |
8 or 16 µM | 24 h | Increased Grp78 (HSPA5) mRNA levels | [54] | ||
BNL CL.2 cells | 15 µM | 3 h | Increased liver HSP70 protein levels | [45] | |
ICR mice | 10 mg/kg body weight (intraperitoneal injection) | 8 weeks | |||
A549 | 0.5 µM | 2–24 h | Increased Grp78 (HSPA5) protein levels | [55] | |
HSP90 | BEAS-2B cells | 1 µM | 48 h | Decreased Hsp90α (HSPC1) protein levels. Unchanged Hsp90α (HSPC1) mRNA levels | [47] |
10 µM | 4 h | Decreased HSP90A (HSPC1) mRNA levels | [46] | ||
Primary culture of rat granulosa cells | 12 or 24 h | Decreased HSP90 protein levels | [52] | ||
L-02 cells | 16 or 32 µM | 24 h | Decreased HSP90 protein levels | [53] | |
A549 | 600 µM | 2 h | Increased TRAP1 (HSPC5) mRNA levels | [56] | |
HSP100 | Rat lung epithelial cells | 10 µM | 24 h | Increased HSP105 protein levels | [42] |
1 A549, cell line established from a human lung adenocarcinoma; BEAS-2B, cell line established from human bronchial epithelium; BNL CL.2, cell line established from embryonic murine liver tissue; HaCaT, keratinocytes cell line established from human skin; HepG2, cell line established from a human hepatocellular carcinoma; HT29, cell line established from a human colorectal adenocarcinoma; L-02, cell line established from human embryonic liver tissue. 2 Cr(VI) was added as a K2Cr2O7 or Na2CrO4 aqueous solution. Of note, for several studies, Cr(VI) concentration values are ambiguous, as the expressions “x μM Cr(VI)” and “x μM potassium dichromate” were used indistinguishably, even though a given potassium dichromate concentrations corresponds to a Cr(VI) concentration twice that value. 3 For designations, see Section 3.1.